Trials / Active Not Recruiting
Active Not RecruitingNCT06939296
A Research Study of VCT220 in Adult Chinese Participants With Obesity
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight or Obese Participants
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 840 (actual)
- Sponsor
- Vincentage Pharma Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess how VCT220 tablets affect the bodyweight in obese or overweight adult participants. Participant will be randomly assigned to the high-dose group, low-dose group, or placebo group. Each participant will take the study drug orally once daily for 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VCT220 | A small molecule GLP-1R drug, film coated tablet |
| DRUG | Placebo | Placebo tablets |
Timeline
- Start date
- 2024-12-24
- Primary completion
- 2025-11-25
- Completion
- 2026-03-31
- First posted
- 2025-04-22
- Last updated
- 2026-03-27
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06939296. Inclusion in this directory is not an endorsement.